A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-21

Study Completion Date

2024-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant T-VEC in High Risk Early Melanoma

NCT04427306

Melanoma

SUSPENDED PHASE2

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704

Melanoma

COMPLETED PHASE3

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

NCT03064763

Unresectable Stage IIIB-IV Malignant Melanoma

COMPLETED PHASE1

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease

NCT04330430

Melanoma Stage III Melanoma Stage IV

COMPLETED PHASE2

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

NCT02366195

Unresected Stage IIIb to IVM1c Melanoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Merkel Cell Carcinoma Other Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy

Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10\^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10\^8 pfu/mL.

Group Type EXPERIMENTAL

TALIMOGENE LAHERPAREPVEC (TVEC)

Intervention Type DRUG

Hypofractionated Radiotherapy

Intervention Type RADIATION

Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy

Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.

Group Type EXPERIMENTAL

TALIMOGENE LAHERPAREPVEC (TVEC)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TALIMOGENE LAHERPAREPVEC (TVEC)

Intervention Type DRUG

Hypofractionated Radiotherapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Man or woman ≥ 18 years old
* Life expectancy \> 4 months
* Histopathologically confirmed melanoma, Merkel cell carcinoma or other solid tumor malignancy
* Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis not suitable for surgical resection
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
* Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis that is amenable to injection and irradiation and \> 10 mm in longest dimension

° Cutaneous metastasis in a region of previous radiation therapy is amenable to radiation therapy as part of this protocol if at least 6 months has elapsed since prior radiotherapy and the dose of radiotherapy previously administered did not exceed an equivalent dose of 60 Gy in 2 Gy equivalent fractions at the skin surface (using linear-quadratic modeling with alpha/beta=11.5)
* Metastasis that is \> 10 mm in longest dimensionor exhibits radiotracer uptake consistent with metastasis on PET/CT
* Adequate coagulation function (platelet count \>50 k/mcL, international normalized ratio of \< 1.5)
* Resolution or stabilization of clinically significant adverse events from prior therapy
* Able to provide valid written informed consent

Exclusion Criteria

* Active herpetic skin lesions or prior complications of HSV-1 infection (such as herpetic keratitis, herpetic encephalitis)
* Receipt of a therapeutic anticoagulant
* Receipt of live vaccine within 28 days of planned first dose of TVEC
* Receipt of another cancer therapy (targeted therapy, chemotherapy, investigational therapy, immunotherapy, radiotherapy or surgery) which is yielding an overall response (by response criteria in this study)

° Patients with stable or progressing disease (as determined by at least 2 consecutive assessments at 6-week interval) can continue to receive the same therapy during treatment as part of this protocol
* History of symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) requiring systemic treatment (for example corticosteroids or immunosuppressants); replacement therapy (for example, thyroxine, insulin) is not considered a systemic treatment
* History of high grade (CTCAE ≥ Grade 3) immune mediated adverse event from prior cancer immunotherapy
* History of CTCAE ≥ Grade 2 immune mediated endocrinopathy from prior cancer immunotherapy
* Intermittent or chronic use of oral or intravenous antiherpetic drug (such as acyclovir)
* Active or chronic hepatitis B or C infection

° Previously infected, with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion
* Known human immunodeficiency virus (HIV) infection
* Known leukemia or lymphoma
* Common variable immunodeficiency
* Patients requiring chronic high dose immunosuppressants including steroids (prednisone daily equivalent of ≥ 10 mg)
* Known severe congenital or acquired cellular or humoral immunodeficient or immunocompromised patients
* High likelihood of protocol non-compliance (in opinion of investigator)
* Woman of childbearing potential unwilling to use effective contraception during protocol treatment and for 3 months after last dose of Talimogene Laherparepvec
* Woman of childbearing potential that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of Talimogene Laherparepvec

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No